Routine HIV Screening in Texas: Implementing the 2010 National HIV/AIDS Strategy
Broadening its scope beyond risk-based targeted testing (RBTT), Texas expanded its testing strategies to include RS for patients ≥13 years in healthcare settings. Successful RS requires collaborating with healthcare setting leadership teams and identifying champions in those settings, utilizing lab-based testing, incorporating RS into electronic medical systems, and connecting healthcare settings with HIV medical services for linkage-to-care.
Using these methods, Texas works with over 100 healthcare settings performing RS. From 2008-2013, Texas exceeded one million routine HIV tests. Of those tested, 52% were female, 41% Hispanic, 30% Black and 45% aged 19-34. The RS positivity rate is 0.9% with 75% of the HIV-infected persons being male, 52% Black, and 41% aged 19-34.
Universally incorporating RS as a testing strategy can help the United States effectively implement the NHAS goals: new infections are identified, patients are linked-to-care and race and ethnic minorities are tested, thereby identifying patients with HIV-related disparities. It is recommended and feasible for other jurisdictions to adopt integrated RS as a standard of medical care. Texas’ method serves as a model for other jurisdictions. Likewise, the medical community early adopters can serve as champions for other healthcare settings by facilitating implementation.
Learning Areas:Implementation of health education strategies, interventions and programs
List at least 2 essential strategies for implementing routine HIV screening as a standard of care in healthcare settings.
Keyword(s): HIV/AIDS, Health Systems Transformation
Qualified on the content I am responsible for because: I have been the lead program coordinator for the Routine HIV Screening Program since its initation in 2008. In addition I have worked with HIV/STDs in direct care, program administration, and grant management for over twenty-six years.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.